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Introduction
Vascular cell adhesion molecule–1 (VCAM-1) is a transmem-
brane protein of the immunoglobulin superfamily expressed on 
blood vessels after endothelial cell (EC) stimulation by inflam-
matory cytokines such as tumor necrosis factor– (TNF-; 
Osborn et al., 1989). VCAM-1 mediates leukocyte binding to 
the vascular endothelium via 41 or 47 integrins, where 
signaling events triggered by VCAM-1 and integrin binding 
contribute to the development of atherosclerosis and rheuma-
toid arthritis (Carter and Wicks, 2001; Libby, 2002). VCAM-1 
is also expressed on the mouse embryo allantois and binds to 
41 integrin on the chorion to facilitate chorioallantoic fusion 
and placental development (Gurtner et al., 1995; Kwee et al., 
1995; Inman and Downs, 2007). TNF- triggers increased 
VCAM-1 production via several intracellular signaling cascades, 
including MAPK and nuclear factor– light chain enhancer of 
activated B cells (NF-B) pathways (Pober, 2002; Karin and 
Gallagher, 2009). These signaling cascades affect multiple tran-
scription factors, including activating protein complex–1 (AP-1), 
NF-B, and GATA-binding proteins that bind to the VCAM-1 
promoter (Ahmad et al., 1998; Molkentin, 2000; Minami and 
Aird, 2001). It is a combination of transcription factor phos-
phorylation and stability that contributes to TNF-–induced 
VCAM-1 promoter activation.
TNF-–induced signaling is highly context dependent, 
triggering either cell death (cytotoxic activity) or cell activation 
(proinflammatory activity; MacEwan, 2002). Costimulatory 
signals from the ECM play an active role in preventing TNF- 
cytotoxic activity and also a permissive function in facilitating 
TNF- proinflammatory EC activation (Bieler et al., 2007). 
Transmembrane integrin receptors bind to ECM proteins and 
Vascular cell adhesion molecule–1 (VCAM-1) plays important roles in development and inflammation. Tumor necrosis factor– (TNF-) and focal adhe-
sion kinase (FAK) are key regulators of inflammatory and 
integrin–matrix signaling, respectively. Integrin costimula-
tory signals modulate inflammatory gene expression, but 
the important control points between these pathways 
remain unresolved. We report that pharmacological FAK 
inhibition prevented TNF-–induced VCAM-1 expression 
within heart vessel–associated endothelial cells in vivo, 
and genetic or pharmacological FAK inhibition blocked 
VCAM-1 expression during development. FAK signaling 
facilitated TNF-–induced, mitogen-activated protein kinase 
activation, and, surprisingly, FAK inhibition resulted in the 
loss of the GATA4 transcription factor required for TNF-–
induced VCAM-1 production. FAK inhibition also triggered 
FAK nuclear localization. In the nucleus, the FAK-FERM 
(band 4.1, ezrin, radixin, moesin homology) domain bound 
directly to GATA4 and enhanced its CHIP (C terminus of 
Hsp70-interacting protein) E3 ligase–dependent poly-
ubiquitination and degradation. These studies reveal new 
developmental and anti-inflammatory roles for kinase-
inhibited FAK in limiting VCAM-1 production via nuclear 
localization and promotion of GATA4 turnover.
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dependent on C terminus of Hsp70-interacting protein (CHIP) 
E3 ligase expression. As FAK-FERM also forms a complex 
with CHIP, our experiments reveal a novel regulation of GATA4 
by a kinase-independent scaffolding role of nuclear FAK as 
part of anti-inflammatory effects of FAK inhibition.
Results
Control of TNF-a–stimulated VCAM-1 
expression by FAK
ECs that line blood vessels rapidly respond to environmental 
changes (Weis and Cheresh, 2011). Vessel-associated changes 
in VCAM-1 expression occur rapidly in response to inflamma-
tory stimuli, but the role of FAK signaling in mediating these 
events remains unknown. As FAK activity facilitates TNF-–
stimulated interleukin-6 (IL-6) gene expression in cultured cells 
(Funakoshi-Tago et al., 2003; Schlaepfer et al., 2007), in vivo 
signaling experiments were performed in mice to determine the 
effect of FAK inhibition of TNF-–induced VCAM-1 expres-
sion. Increased VCAM-1 levels were detected within 6 h in 
mouse heart or lung lysates after tail vein injection of TNF- 
(Figs. 1 A and S1). Pretreatment of mice with a pharmaco-
logical FAK inhibitor (FAK-I) significantly inhibited VCAM-1 
expression and FAK Y397 phosphorylation but not FAK ex-
pression in heart and lung lysates (Figs. 1 B and S1). In heart 
lysates, oral FAK-I administration also prevented FAK pY576 
phosphorylation within the kinase domain activation loop 
(Fig. 1 A). Staining of heart sections revealed that pY576 FAK 
phosphorylation is maximal in association with ECs and that 
EC-associated FAK pY576 is significantly inhibited by FAK-I 
treatment within control and TNF-–stimulated mice (Figs. 1 
[C and D] and S2 A). Analyses of heart sections revealed sig-
nificantly increased EC-associated VCAM-1 expression upon 
TNF- stimulation and decreased VCAM-1 staining after FAK-I 
administration (Figs. 1 [E and F] and S2 B). Together, these 
data indicate that TNF-–mediated VCAM-1 expression within 
blood vessel–associated ECs is dependent on FAK activity.
FAK activity controls VCAM-1 expression 
during mouse development
VCAM-1 expression on the developing mouse embryo allantois 
promotes binding to 41 integrin on chorion membrane, and 
this union facilitates chorioallantoic fusion (Inman and Downs, 
2007). FAK-KD knockin mutation results in lethality at embry-
onic day 9.5 (E9.5; Lim et al., 2010a), with embryos exhibiting 
an enlarged and unfused allantois (Fig. 2 A). FAK-I administra-
tion to pregnant mice also results in E9.5 embryo lethality with 
defective allantois structures (Fig. 2 B). FAK-KD embryos fail to 
form somites, exhibit gross defects in head and heart structures, 
and form a rudimentary gut cavity (Fig. 2 C). Comparisons of 
mRNAs within FAK–wild type (WT) and FAK-KD embryos by 
array analyses revealed several targets that differed in expression 
greater than twofold. In particular, VCAM-1 mRNA levels were 
reduced 7.4 fold in FAK-KD embryos (Table 1). Gene ontology 
analyses of the mRNA array data revealed functional annotated 
differences that connect FAK activity to a leukocyte extravasa-
tion signaling group (Fig. S3). Other connections to endocytosis, 
facilitate the activation of nonreceptor protein tyrosine kinases 
(PTKs), MAPKs, and NF-B pathways (Schwartz, 2001). Integrin- 
mediated signaling supports TNF-–induced cell survival and 
gene expression (Fornaro et al., 2003). This requires NF-B ac-
tivation (Beg and Baltimore, 1996) and PTKs such as Syk, and 
Src family PTKs have been linked to TNF-–induced NF-B 
activation (Huang et al., 2003; Takada and Aggarwal, 2004). 
However, integrin and FAK PTK activation are more strongly 
associated with TNF-–induced MAPK activation (Short et al., 
1998; Schlaepfer et al., 2007; Young et al., 2010). Although 
PTK activity is needed for TNF-–induced VCAM-1 expres-
sion (Weber et al., 1995; May et al., 1996), the PTKs facilitat-
ing these signaling events remain unknown.
FAK is comprised of an N-terminal FERM (band 4.1, 
ezrin, radixin, moesin homology) domain, central PTK region, 
and a C-terminal (CT) domain that links it to integrins (Mitra 
et al., 2005; Schaller, 2010). FAK is activated by integrin, growth 
factor, and G protein–linked and cytokine stimuli that increase 
FAK tyrosine phosphorylation at tyrosine (Y) 397, Y576, Y861, 
and Y925 and link FAK to MAPK activation (Schlaepfer and 
Mitra, 2004). Global or EC-specific FAK knockout results in 
embryonic lethality associated with vascular defects (Ilic et al., 
2003; Shen et al., 2005; Braren et al., 2006). A p53 tumor sup-
pressor–dependent block in cell proliferation is associated with 
the FAK knockout phenotype (Lim et al., 2008). However, the 
presence of the FAK-related Pyk2 PTK in cells without FAK re-
duces effects of FAK loss on p53 and angiogenesis (Weis et al., 
2008; Lim et al., 2010b). Although recent studies using condi-
tional FAK knockout in ECs prevent tumor-induced vascular 
permeability (Lee et al., 2010) and angiogenesis (Tavora et al., 
2010), the in vivo signaling connections for FAK in mediating 
these effects remains unclear.
Knockin mouse models have revealed that FAK activity 
is critical for developmental vasculogenesis (Lim et al., 2010a; 
Zhao et al., 2010). Additionally, pharmacological FAK inhibition 
suppresses tumor- and growth factor–stimulated angiogenesis 
(Roberts et al., 2008; Weis et al., 2008). FAK kinase-dead (KD) 
knockin mutation is embryonic lethal, and FAK-KD fibroblasts 
exhibit defects in cell polarity and motility but not cell pro-
liferation (Lim et al., 2010a). FAK-KD protects primary ECs 
from increased apoptosis through a mechanism that involves 
FAK-FERM–mediated nuclear localization, binding to p53, and 
enhancement of murine double minute 2 (Mdm2) E3 ligase–
dependent p53 ubiquitination and proteasome degradation (Lim 
et al., 2010b). Thus, nuclear FAK can regulate cell proliferation 
and survival by facilitating p53 turnover in a kinase-independent 
manner. As nuclear-localized FAK contributes to chromatin re-
modeling and gene expression (Luo et al., 2009), support for a 
functional role for FAK in the nucleus is growing.
Herein, we show that FAK inhibition prevents TNF-–
induced and developmental VCAM-1 expression. Although FAK 
activity facilitates TNF-–induced MAPK activation, genetic 
or pharmacological FAK inhibition also resulted in the loss of 
the GATA4 transcription factor required for TNF-–induced 
VCAM-1 production. We find that inhibited FAK accumulates 
in the nucleus, and FAK-FERM binds to the GATA4 transcrip-
tion factor and enhances GATA4 ubiquitination and is degradation 
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effects, as FAK-I significantly inhibited TNF-–induced VCAM-1 
promoter luciferase activity (Fig. 3 B). Knockdown of FAK 
expression also significantly inhibited TNF-–induced VCAM-1 
protein and mRNA expression (Fig. 3, C and D). As FAK-I treat-
ment of HUVECs also prevented IL-1–stimulated VCAM-1 
expression (Fig. 3 E), our experiments show that FAK functions 
as a common signaling component regulating inflammatory 
cytokine-stimulated VCAM-1 expression.
FAK facilitates TNF-a–induced MAPK  
but not NF-B activation
TNF- activates extracellular-regulated kinase (ERK) MAPKs, 
JNK MAPKs, and p38 MAPKs as well as NF-B to regulate 
gene expression (Karin and Gallagher, 2009). To determine the sig-
naling consequences of FAK inhibition, comparisons of FAK-WT 
and FAK-KD MEFs or DMSO (control) and FAK-I–treated 
HUVECs were performed (Fig. 4). TNF- rapidly and equally 
promoted NF-B pS536 phosphorylation in both control and 
FAK-I–treated cells (Fig. 4, A and B). Regulatory IkB was 
rapidly degraded after TNF- addition (Fig. 4, A and B), and 
electrophoretic mobility shift assays (EMSAs) revealed equiv-
alent TNF-–stimulated NF-B DNA binding in FAK-KD MEFs 
and FAK-I–treated HUVECs compared with FAK-WT and 
DMSO-treated controls (Fig. S4). In vivo, FAK-I significantly 
inhibited TNF-–induced FAK pY397 phosphorylation but did 
not alter TNF-–stimulated NF-B DNA binding in mouse lung 
lysates (Figs. 4 C and S5). Despite the importance of NF-B in 
tight junction, integrin, and Rho signaling groups were also iden-
tified. Verification of VCAM-1 protein expression differences 
between FAK-WT and FAK-KD embryos was obtained by im-
munostaining of hearts and allantois (Fig. 2 D) and immunoblot-
ting of embryos lysates (Fig. 2 F). FAK-I treatment of pregnant 
mice also prevented embryo-associated VCAM-1 expression 
(Fig. 2 E) and FAK pY397 phosphorylation (Fig. 2 F). Notably, 
primary mouse embryonic fibroblasts (MEFs) or ECs isolated 
from FAK-WT or FAK-KD embryos showed that genetic inhi-
bition of FAK activity prevented TNF-–induced VCAM-1 
expression (Fig. 2, G and H). Although developmental signals 
regulating VCAM-1 expression are complex and involve multi-
ple transcription factors (Ferdous et al., 2011), our experiments 
support the importance of FAK activity in controlling both devel-
opmental and TNF-–induced VCAM-1 expression in mice.
FAK inhibition prevents cytokine-stimulated 
VCAM-1 expression in human ECs
Regulation of mouse and human VCAM-1 expression share 
both similarities and mechanistic differences (Minami and 
Aird, 2001). To determine whether FAK is also important in 
human TNF-–induced human VCAM-1 expression, signal-
ing experiments were performed with human umbilical vein 
ECs (HUVECs). FAK-I treatment prevented TNF-–mediated 
VCAM-1 expression in a dose-dependent manner with an IC50 
of 0.5 µM that paralleled inhibition of FAK Y397 phosphory-
lation (Fig. 3 A). This effect was a result in part of transcriptional 
Figure 1. TNF-a–induced VCAM-1 expression within 
heart-associated ECs in vivo is dependent on FAK 
activity. PBS or TNF- (0.02 mg/kg) was tail vein in-
jected into mice, and, after 6 h, tissues were analyzed 
by immunoblotting or staining. Where indicated, FAK-I 
(100 mg/kg, PND-1186) was administered 3 h before 
starting experiments. (A) Immunoblotting of heart 
lysates shows increased VCAM-1 expression and 
FAK Y397 or FAK Y576 phosphorylation upon TNF- 
stimulation in vivo. FAK-I addition prevents VCAM-1 
production and FAK tyrosine phosphorylation but no 
change in FAK expression. Internal loading controls 
for each gel are shown by anti-actin immunoblotting. 
(B) Heart-associated VCAM-1 or FAK activation (pY397) 
was determined by immunoblotting (see Fig. S1) and 
expressed as a ratio to actin or total FAK, as deter-
mined by densitometry, respectively. Values are 
means (±SD) from six mice, representing two indepen-
dent experiments (***, P < 0.001). (C) In vivo signal-
ing assays were performed as in A, and heart sections 
were analyzed by combined staining for activated 
FAK (pY576) and ECs (CD31). Bar, 20 µm. (D) Mean 
correlation of pixel intensities from anti–pY576 FAK and 
anti-CD31 staining of heart sections, as shown in C. 
(E) Visualization of EC-associated VCAM-1 expres-
sion. Heart sections were analyzed by combined 
staining for VCAM-1 and ECs (CD31). A merged 
image is shown. Bar, 20 µm. (F) Mean correlation 
of pixel intensities from anti–VCAM-1 and anti-CD31 
staining of heart sections, as shown in C. (D and F) 
10 full-frame images were analyzed per experimental 
group for calculations of VCAM-1 and pY576 FAK as-
sociated with CD31 staining (±SEM; ***, P < 0.001; 
****, P < 0.0001).
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MEF reconstitution experiments have verified the importance 
of FAK activity and Y397 FAK phosphorylation in facilitat-
ing TNF-–stimulated ERK/MAPK activation and IL-6 gene 
expression (Schlaepfer et al., 2007), our experiments evaluating 
ERK/MAPK and VCAM-1 extend this TNF- and FAK signal-
ing connection to HUVECs and to mice.
FAK inhibition alters GATA4 transcription 
factor levels
To establish the signaling linkage between FAK, MAPK, and 
the regulation of VCAM-1 transcription, rescue assays were 
performed by transient transfection of FAK-WT or activators 
of MAPKs (constitutively active MEK1, MKK4, or MEKK1) 
in FAK-KD MEFs or HUVECs treated with FAK-I. Unexpect-
edly, neither FAK-WT nor active MAPK alone or in com-
bination was able to increase VCAM-1 expression upon TNF- 
stimulation (unpublished data). As VCAM-1 production is 
transcriptionally regulated, we investigated whether FAK inhi-
bition may alter the profile of VCAM-1–associated transcription 
factors in cells (Ahmad et al., 1998; Molkentin, 2000; Minami 
and Aird, 2001). Although genetic or pharmacological FAK inhi-
bition did not prevent NF-B activation upon TNF- stimulation 
promoting TNF-–induced VCAM-1 gene transcription (Karin 
and Gallagher, 2009), FAK inhibition did not detectably alter 
NF-B activation.
Instead, comparisons of WT and FAK-KD MEFs or 
FAK-I–treated HUVECs revealed that FAK-I reduced TNF-–
stimulated JNK/MAPK and ERK/MAPK activation at 5 and 
15 min (Fig. 4, A and B). FAK-I treatment results in the eleva-
tion of total FAK expression but not pY397 FAK phosphoryla-
tion in HUVECs (Fig. 4 B). In lung lysates, pretreatment of 
mice with FAK-I significantly prevented TNF-–induced ERK/
MAPK activation in vivo (Figs. 4 C and S5), and a previous 
study showed that pharmacological ERK inhibition prevented 
TNF-–induced VCAM-1 expression in ECs (Fitau et al., 2006). 
Our results support the conclusion that FAK activity facilitates 
TNF- signaling to MAPKs needed for VCAM-1 expression. 
This role for FAK may be related to cross-talk between integrin 
and cytokine signaling pathways, as TNF- signaling to ERK/
MAPK (Fig. 4 D), induction of VCAM-1 expression (Fig. 4 E), 
and FAK Y397 phosphorylation (Fig. 4, D and E) are prevented 
when MEFs are deprived of matrix-mediated cell adhesion. 
Serum addition limited suspension-induced cell death, as deter-
mined by annexin V staining (unpublished data). As FAK/ 
Figure 2. FAK activity controls developmental VCAM-1 
expression. (A) FAK-KD embryos at E9.5 exhibit an enlarged 
and unfused allantois (arrow) compared with normal FAK-
WT embryos where chorioallantoic fusion has occurred. 
(B) Treatment of pregnant female mice with FAK-I (100 mg/kg, 
PND-1186 from E7.5 to E9.5) but not vehicle (water) results 
in lethality of embryos (E9.5), exhibiting defective allan-
tois formation (arrow). (C) Sagittal sections of E9.5 WT and 
FAK-KD embryos. FAK-KD embryos do not form somites (S) 
and display gross defects in head, heart (H), and allantois (Al). 
The arrow indicates the chorion (Ch) membrane. G, gut; 
N, neural cell. (D) Whole-mount anti–VCAM-1 staining of 
embryos at E9.5 reveals no VCAM-1 expression in FAK-KD 
compared with FAK-WT embryos. HD, head. (E) Lack of 
VCAM-1 staining in FAK-I (100 mg/kg, PND-1186 from E7.5 
to E9.5) compared with vehicle-treated embryos at E9.5. 
(A–E) Bars, 100 µm. (F–H) VCAM-1 protein expression and 
FAK activation are inhibited within FAK-KD and FAK-I–treated 
embryos. Immunoblotting of E9.5 embryo lysates reveals 
VCAM-1 levels (left) and FAK phosphorylation (pY397; right) 
with actin and total FAK as loading controls. Results from 
MEFs (G) or ECs (H) show that TNF- (10 ng/ml, 16 h) induces 
VCAM-1 expression in FAK-WT but not FAK-KD cells, as de-
termined by immunoblotting with pY397 FAK, total FAK, and 
actin levels, shown as controls.
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(not depicted) and resulted in an 90% loss of GATA4 within 
6 h without effects on GATA6 (Fig. 5 B). Interestingly, these 
FAK-I–triggered changes in GATA4 expression occurred with-
out alterations in GATA4 mRNA levels (Fig. 5 C). Thus, inhibi-
tion of FAK selectively affects GATA4 protein but not mRNA 
levels in cells.
FAK and GATA4 rescue TNF-a–induced 
VCAM-1 expression in FAK-KD MEFs
To determine the significance of GATA4 loss upon FAK inhibi-
tion, FAK-WT and GATA4 alone or in combination were 
transfected into FAK-KD MEFs, and the effect on VCAM-1 
production was evaluated in the presence or absence of TNF- 
stimulation (Fig. 5 D). Notably, only the combination of FAK-WT 
and GATA4 with TNF- stimulation was able to promote 
VCAM-1 expression. Additionally, siRNA knockdown of GATA4 
in FAK-WT MEFs significantly reduced TNF-–induced 
VCAM-1 protein and mRNA levels (Fig. 5, E and F). Quanti-
tative PCR (Q-PCR) was used to confirm that GATA4 and 
VCAM-1 mRNA were significantly suppressed after TNF- 
stimulation by siRNA to GATA4 compared with control siRNA 
transfection (Fig. 5, G and H). In vivo, GATA4 and VCAM-1 
protein levels were increased in heart lysates after TNF- stimula-
tion, and this was significantly inhibited by FAK-I administration 
(Fig. 4), immunoblotting revealed the absence of GATA4 
expression in FAK-KD MEFs, whereas GATA6 was equally 
expressed in FAK-WT and FAK-KD MEFs (Fig. 5 A). Further, 
FAK-I treatment of cells also resulted in the selective loss 
of GATA4 but not GATA6 expression by >50% within 3 h 
Table 1. Differences in target mRNAs from FAK-WT and FAK-KD 
embryos during development
Protein name Fold reduction (WT/KD)
Tropomodulin-1 13.1
VCAM-1 7.4
Caveolin-1 6.4
Robo-4 4.9
Rgs5 4.7
CD31 3.6
WAS 4.3
ESAM-1 2.7
ICAM-2 2.6
-SMA 2.3
SEMA6B 2.1
Illumina MouseWG-6 v2.0 Expression BeadChip analyses (45,200 targets) 
were performed. Selected mRNAs with greater than twofold change are 
shown. WAS, Wiskott–Aldrich syndrome; ESAM-1, endothelial selective 
adhesion molecule–1; ICAM-2, intercellular adhesion molecule–2; -SMA, 
–smooth muscle actin.
Figure 3. FAK activity is essential for proinflamma-
tory cytokine-mediated VCAM-1 expression. (A) TNF-
–induced (10 ng/ml, 16 h) VCAM-1 is prevented by 
FAK-I (PF271) treatment of HUVECs in a dose-dependent 
(0.1–2.5 µM FAK-I) manner. VCAM-1, pY397 FAK, 
total FAK, and actin levels were determined by immuno-
blotting. (B) TNF-–induced VCAM-1 promoter ac-
tivity is blocked by FAK inhibition. HUVECs were 
transfected with pGL3 promoterless luciferase (con-
trol) or pGL3 fused with the human VCAM-1 pro-
moter, stimulated with TNF-, and treated with FAK-I 
(1 µM PF271), as indicated, and relative luciferase 
activity (arbitrary units [a.u.]) is shown. Values are 
means (±SD) from three independent experiments. 
(C) FAK knockdown prevents VCAM-1 expression. 
HUVECs were transduced with lentiviral Scr or anti-
FAK short hairpin RNA (shRNA) and stimulated with 
TNF-. FAK and VCAM-1 and actin expression levels 
were determined by immunoblotting, and densitom-
etry values of VCAM-1 relative to actin are means 
(±SD; n = 3; ***, P < 0.001). (D) VCAM-1 mRNA 
levels to GAPDH were determined by Q-PCR (±SD; 
n = 3; ***, P < 0.001) in experiments, as described 
in C. (E) FAK activity is required for IL-1–induced 
VCAM-1 expression. HUVECs were stimulated with 
20 ng/ml IL-1 and 10 ng/ml TNF-, and FAK-I 
(1 µM PF271) was added as indicated. After 16 h, 
VCAM-1, pY397 FAK, and actin levels were evalu-
ated by immunoblotting.
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or ubiquitination and proteasome degradation (Brewer and 
Pizzey, 2006). The loss of GATA4 expression by FAK-I treat-
ment was reversed by addition of a cell-permeable proteasome 
inhibitor (MG132; Fig. 6 A), supporting the notion that FAK 
inhibition may promote enhanced GATA4 degradation. Nota-
bly, FAK can also promote p53 tumor suppressor degradation 
to mice (Fig. 5 I). Together, these results support the importance 
of GATA4 in TNF-–induced VCAM-1 expression and suggest 
that loss of GATA4 associated with FAK inhibition prevents 
VCAM-1 production.
Regulation of GATA4 protein levels can occur through 
various posttranslational mechanisms, including phosphorylation 
Figure 4. TNF-a–induced MAPK but not NF-B activation is dependent on FAK activity in vitro and in vivo. (A and B) FAK-WT or FAK-KD MEFs (A) and 
HUVECs pretreated with DMSO or FAK-I (1 µM PF271; B) were stimulated with 10 ng/ml TNF- for the indicated times, and lysates were prepared for 
immunoblotting. Blots for activated FAK (pY397), total FAK, activated NF-B (pS536), activated JNK (p-JNK and pT183/pY185), activated ERK (pERK and 
pT202/pY204), IB, and actin are shown. Internal loading controls for each gel are shown by anti-actin, anti-GAPDH, anti-talin, or reprobing membranes 
with antibodies to total NF-B, JNK2, or total ERK1/2 immunoblotting. (C) PBS or TNF- (0.02 mg/kg) was tail vein injected into mice, and, after 5 min 
(FAK and ERK activation) or 3 h (NF-B activation), lung tissue was analyzed by immunoblotting or EMSA. Where indicated, FAK-I (100 mg/kg, PND-
1186) was administered 3 h before starting experiments. Values, measured by densitometry, are means (±SD) from six mice, representing two independent 
experiments. ***, P < 0.001. (D and E) MEFs were replated onto FN dishes or held in suspension (Sus) for 1 h before TNF- (10 ng/ml) addition for 
15 min (D) or 6 h (E) before protein cell lysis. Blots for activated ERK (pERK and pT202/pY204), activated FAK (pY397), total FAK, and actin are shown. 
Anti-GAPDH blotting is shown as loading controls.
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FAK-FERM binds GATA4 and enhances 
GATA4 ubiquitination
Localization of FAK to integrin-enriched sites of adhesion oc-
curs via the FAK C-terminal domain, whereas the FAK-FERM 
domain can target FAK to the nucleus (Lim et al., 2008). Ade-
noviral (Ad)-mediated overexpression experiments in human 
293T cells revealed that FAK-WT, FAK-KD, and FAK-FERM 
but not FAK-CT associated with endogenous GATA4 by coim-
munoprecipitation (Fig. 6 D). In vitro translation of various 
FAK constructs combined with binding assays using GST fu-
sion proteins of GATA4 N-terminal and CT domains revealed 
direct binding between FAK-WT, FAK-KD, and FAK-FERM 
with the N-terminal domain of GATA4 (Fig. 6 E). No binding 
was detected between the FAK kinase domain and GATA4.
(Lim et al., 2008). Cell stress triggers FAK nuclear localization, 
a nuclear FAK–p53 complex, and FAK-enhanced Mdm2 E3 
ligase–dependent ubiquitination and degradation of p53 (Lim 
et al., 2008). In FAK-KD MEFs, FAK is localized to sites of 
adhesion as well as to the nucleus (Lim et al., 2010a). Biochemical 
separation of FAK-WT and FAK-KD MEFs into cytosolic 
and nuclear fractions revealed elevated levels of FAK-KD in 
the nucleus (Fig. 6 B). Importantly, FAK-I treatment of cells 
could trigger enhanced FAK nuclear accumulation within 3–6 h 
(Fig. 6 C). Interestingly, the timing of FAK nuclear localiza-
tion upon FAK-I addition parallels the time course of GATA4 
loss (Figs. 5 B and 6 C). Together, these results show that FAK 
inhibition promotes increased FAK nuclear accumulation–
correlated loss of GATA4 protein.
Figure 5. FAK inhibition decreases GATA4 
levels needed for TNF-a–induced VCAM-1 
expression. (A) Steady-state GATA4 and GATA6 
levels in FAK-WT and FAK-KD MEFs, as deter-
mined by immunoblotting with actin as a con-
trol. (B) FAK-WT MEFs treated with DMSO or 
FAK-I (1 µM PF271, 6 h) and lysates blotted 
for GATA4 or GATA6. Anti-GAPDH blotting is 
shown as loading controls. (C) GATA4 mRNA 
levels to GAPDH were determined by Q-PCR 
(±SD; n = 3) in experiments, as described in B. 
(D) Rescue of TNF-–induced VCAM-1 expres-
sion in FAK-KD MEFs by combined FAK-WT 
and GATA4 expression. Combinations of GFP-
FAK and GATA4 were transfected into FAK-KD 
MEFs. After 24 h, cells were stimulated with 10 
ng/ml TNF-, as indicated, and FAK, VCAM-1, 
and GATA4 immunoblotting was performed 
at 40 h. (E) FAK-WT MEFs were transfected 
with Scr or GATA4 (G4) siRNA and, after 48 h, 
stimulated with TNF- (10 ng/ml, 6 h), and im-
munoblotting was performed for VCAM-1 and 
GATA4. Anti-actin and anti-GAPDH blotting 
are shown as loading controls. (F) Densitometry 
analyses of VCAM-1 protein levels relative to 
actin, as described in E. (±SD; n = 2; ***, P < 
0.001). (G and H) MEFs were transfected with 
Scr or GATA4 siRNA and stimulated with TNF-, 
as described in E. GATA4 (G) or VCAM-1 
(H) mRNA levels to GAPDH were determined 
by Q-PCR (±SD; n = 3; ****, P < 0.0001). 
(I) PBS or TNF- (0.02 mg/kg) was tail vein 
injected into mice, and, after 6 h, heart lysates 
were analyzed by immunoblotting for VCAM-1, 
GATA4, pY397 FAK, total FAK, and actin. 
Where indicated, FAK-I (100 mg/kg, PND-1186) 
was administered 3 h before starting experi-
ments. Data are mean densitometry values 
relative to actin (±SD; n = 2; *, P < 0.05; 
**, P < 0.001).
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column. Importantly, FAK-FERM WT but not FAK-FERM 
R177/178A overexpression increased di- and polyubiquitination 
of GATA4 (Fig. 7 D). These results show that FAK-FERM 
nuclear localization is required for efficient GATA4 polyubiqui-
tination. Finally, as GATA4 activation is mediated in part through 
ERK/MAPK phosphorylation of GATA4 S105 (van Berlo et al., 
2011), MEFs were treated with TNF- in the presence or 
absence of FAK-I and evaluated for changes in GATA4 S105 
phosphorylation (Fig. 7 E). Maximal TNF-–induced GATA4 
activation occurred at 1 h, and although FAK-I triggered loss of 
GATA4 protein levels, GATA4 pSer105 phosphorylation was 
also prevented by FAK-I addition. Collectively, these results 
show that FAK inhibition prevents signals leading to GATA4 
phosphorylation and promotes the turnover of GATA4 protein 
as mechanisms limiting TNF-–induced VCAM-1 expression.
Discussion
Induced VCAM-1 expression contributes to vascular inflam-
mation (Libby, 2002). Here, we show through both genetic 
and pharmacological experimental results that FAK activity is 
essential in promoting TNF-–induced VCAM-1 expression. 
These experiments define a new role for nuclear FAK in the 
regulation of inflammation-induced gene expression. Our re-
sults support a model (Fig. 8) whereby under normal signaling 
conditions, FAK functions in the cytoplasm to facilitate 
TNF-–induced MAPK associated with GATA4 Ser105 phos-
phorylation and needed for induction of VCAM-1 expression. 
Notably, overexpression of FAK-WT, FAK-KD, or FAK-
FERM increased GATA4 polyubiquitination (Fig. 6 F). These 
experiments were performed in the presence of MG132 pro-
teasome inhibitor to stabilize and detect polyubiquitinylated 
GATA4 by immunoblotting. Interestingly, treatment of MEFs 
with FAK-I enhanced GATA4 ubiquitination, and this occurred 
equally in FAK-WT and Mdm2/ MEFs (Fig. 7 A). As GATA4 
ubiquitination is mediated in part by the cochaperone/ubiquitin 
E3 ligase CHIP in response to cellular stress (Dai et al., 2003; 
Kobayashi et al., 2007), CHIP/ MEFs were treated with a 
combination of MG132 and FAK-I. No GATA ubiquitination 
was detected in CHIP/ MEFs (Fig. 7 A), and this was rescued 
by CHIP reexpression in combination with FAK inhibition 
(Fig. 7 B). Transient transfection experiments revealed that 
full-length FAK and FAK-FERM, but not FAK-CT, formed a 
complex with CHIP (Fig. 7 C). As FAK-FERM forms a scaf-
fold for p53 and Mdm2 binding to facilitate p53 ubiquitination 
and degradation (Lim et al., 2008), our results support a similar 
model whereby FAK-FERM may also form a complex with 
GATA4 and CHIP to facilitate GATA4 ubiquitination.
FAK-FERM mutations that disrupt nuclear localization 
prevent efficient regulation of p53 (Lim et al., 2008). To deter-
mine whether FAK nuclear localization is important in GATA4 
regulation, FAK-FERM WT or FAK-FERM R177A/R178A 
(point mutations that prevent nuclear localization) was evaluated 
for effects on GATA4 ubiquitination (Fig. 7 D). Analyses of 
protein lysates denatured in 8 M urea revealed equal capture and 
elution of ubiquitinylated proteins on a nickel affinity–binding 
Figure 6. Inhibited FAK is nuclear localized, 
and FAK-FERM binds GATA4 to promote GATA4 
ubiquitination in cells. (A) FAK-WT MEFs treated 
with DMSO, FAK-I (1 µM PF271), or FAK-I with 
MG132 (40 µM) for 12 h and lysates blotted 
for GATA4 and actin. (B) FAK-WT and FAK-KD 
MEF lysates were separated into cytosolic (C) or 
nuclear (N) fractions and immunoblotted for FAK, 
PARP, GATA4, and GAPDH. PARP and GAPDH 
are nuclear and cytosolic markers, respectively. 
(C) FAK inhibition promotes FAK nuclear localiza-
tion within 3 h. FAK-WT MEFs were treated with 
FAK-I (1 µM PF271) for the indicated times, and 
fractionated lysates were immunoblotted for FAK, 
PARP, and GAPDH. (D) 293T cells were trans-
duced with Ad-TA, the indicated HA- or Myc-tagged 
FAK-WT, FAK-KD, FAK-FERM, and FAK-CT con-
structs, and association with endogenous GATA4 
was determined by coimmunoprecipitation (IP). 
Immunoblotting shows expression of FAK constructs 
or actin (top) and FAK-FERM association with 
GATA4 (bottom). (E) GATA4 directly binds FAK. 
In vitro translated GFP–tandem affinity probe (TAP), 
FAK-WT, FAK-KD, TAP-FAK-FERM, and TAP-FAK 
kinase domain (386–686) were used in a direct 
binding assay with GST or GST fusions of GATA4 
N terminus or GATA4 C terminus. Streptavidin 
(Strept)-HRP analyses show the amount of FAK 
bound (left) or 10% of input (right). (F) FAK-FERM 
enhances GATA4 ubiquitination. FAK-WT MEFs 
were transduced with Ad-TA, the indicated FAK 
constructs, and flag-tagged GATA4 and treated 
with MG132 (40 µM, 3 h). Whole-cell lysates were 
analyzed for expression of FAK or actin (left), and 
flag tag immunoprecipitates (antibody coupled to 
beads) were evaluated by anti-ubiquitin (Ub) and 
GATA4 immunoblotting.
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administration may result from the intrinsic inhibition of macro-
phage motility as well as stromal-associated mediators such 
as changes in VCAM-1 gene expression. As FAK-Is are being 
evaluated in human clinical trials as agents blocking tumor 
growth and angiogenesis (Schultze and Fiedler, 2010), our ex-
periments evaluating VCAM-1 and a recent study of dominant-
negative FAK inhibition preventing EC-associated E-selectin 
up-regulation (Hiratsuka et al., 2011) support a greater need to 
understand the role of FAK inhibition in altering inflammatory-
associated vascular responses.
A previous study showed that FAK is catalytically acti-
vated by TNF- stimulation of cells (Schlaepfer et al., 2007). 
Although other PTKs are associated with TNF- signaling, past 
studies have linked PTK activity to TNF-–induced NF-B 
activation (Huang et al., 2003; Takada and Aggarwal, 2004). In 
contrast, FAK inhibition selectively reduced TNF- activation 
of MAPKs but had no effect on NF-B activation. Importantly, 
it is signaling from multiple pathways that combine to activate 
AP-1, NF-B, and GATA transcription factors necessary for 
Upon genetic or pharmacological FAK inhibition, FAK accu-
mulates in the nucleus and acts to enhance GATA4 polyubiqui-
tination. Loss of GATA4 prevents TNF-–stimulated VCAM-1 
expression, and this block cannot be rescued by constitutive 
MAPK activation. The FAK-FERM domain promotes FAK 
nuclear localization and direct binding to GATA4 and acts as a 
scaffold to enhance CHIP E3 ligase–dependent GATA4 poly-
ubiquitination, leading to GATA4 degradation. These experi-
ments reveal a novel anti-inflammatory role for nuclear-localized 
and kinase-inhibited FAK in limiting VCAM-1 production 
through the modulation of GATA4 activation and turnover.
Our experiments also expand the role for FAK in mediating 
inflammatory signals. FAK activity promotes TNF-–induced 
IL-6 expression (Funakoshi-Tago et al., 2003; Schlaepfer et al., 
2007), and FAK-I treatment of mice prevents orthotopic breast 
tumor–associated leukocyte infiltration and tumor-associated 
splenomegaly (Walsh et al., 2010). As conditional deletion of 
FAK expression prevents macrophage or neutrophil cell migra-
tion (Owen et al., 2007), anti-inflammatory effects of FAK-I 
Figure 7. FAK-enhanced GATA4 polyubiqui-
tination is dependent on CHIP and FAK-FERM 
nuclear localization. (A) FAK-WT, Mdm2/ 
p53/, and CHIP/ MEFs were transfected 
with flag-tagged GATA4 and treated with 
MG132 (40 µM, 3 h) and FAK-I (1 µM 
PF271), as indicated. Flag tag immuno-
precipitates (IPs) were evaluated by anti-ubiquitin 
(Ub) and GATA4 immunoblotting and show 
no ubiquitination of GATA4 in CHIP/ MEFs. 
(B) CHIP/ MEFs were transfected with HA-
tagged CHIP and flag-tagged GATA4 and 
treated with MG132 (40 µM, 3 h) and FAK-I 
(1 µM PF271). Flag tag immunoprecipitates 
were evaluated by anti-ubiquitin and GATA4 
immunoblotting and show rescue of GATA4 
ubiquitination by CHIP reexpression. Lysates 
show HA-CHIP and actin expression. (C) 293T 
cells were cotransfected with GFP-tagged FAK, 
FAK-FERM, and FAK-CT with HA-CHIP. Coimmuno-
precipitation analyses with antibodies to 
GFP reveal FAK-FERM and CHIP association 
by immunoblotting. Lysates show equal levels 
of GFP-FAK and HA-CHIP expression. (D) 293T 
cells were transfected with GFP-tagged FAK-
FERM WT or FAK-FERM R177A/R178A, flag- 
tagged GATA4, and His-tagged ubiquitin 
and denatured lysates (8 M urea) purified by 
nickel agarose affinity binding. GFP-FERM and 
Flag-GATA4 (with actin and GAPDH as load-
ing controls; left), total eluted ubiquitinated 
proteins (middle), and mono-, di-, and polyubiq-
uitinated GATA4 (right), as determined by 
immunoblotting, are shown. (E) FAK-WT MEFs 
pretreated with DMSO or FAK-I (1 µM PF271, 
30 min) were stimulated with 10 ng/ml TNF- 
for the indicated times, and lysates were pre-
pared for immunoblotting. Blots for activated 
GATA4 (pS105), total GATA4, activated FAK 
(pY397), and actin are shown.
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for FAK-FERM–enhanced GATA4 ubiquitination and not Mdm2. 
FAK-FERM forms a complex with CHIP, but the mechanisms 
for FAK-FERM–enhanced, CHIP-dependent GATA4 ubiqui-
tination remain to be determined. As nuclear-localized FAK 
contributes to chromatin remodeling and gene expression 
(Luo et al., 2009) and FAK-I treatment of cells promotes 
FAK nuclear localization, this kinase-independent function of 
FAK deserves recognition when evaluating results of pharma-
cological FAK inhibition.
Moreover, the specific factors regulating FAK nuclear and 
cytoplasmic shuttling remain unclear. A previous study showed 
that FAK nuclear localization was enhanced in normal cells 
within 30 min of staurosporine addition or disruption of cell–
matrix adhesions (Lim et al., 2008). These conditions are associ-
ated with loss of FAK tyrosine phosphorylation similar to FAK-I 
treatment. As treatment of cells with the nuclear export inhibitor 
leptomycin B results in FAK nuclear accumulation, a cytoplas-
mic pool of FAK likely shuttles in and out of the nucleus. Notably, 
a validated nuclear export sequence is located within the FAK 
kinase domain, and the nuclear localization sequence is within the 
FAK-FERM domain (Ossovskaya et al., 2008). As structural 
experiments show that the FAK-FERM domain makes inhibitory 
contacts to the FAK kinase domain and holds FAK in an inactive 
conformation (Lietha et al., 2007), it is tempting to speculate 
whether this may block FAK kinase domain nuclear export func-
tion in addition to preventing FAK catalytic activation.
In summary, our genetic and pharmacological inhibition 
experiments reveal that FAK activity regulates VCAM-1 gene 
expression during development and expand the role of FAK 
signaling as an essential mediator of TNF-–induced VCAM-1 
production. The regulation of GATA4 by nuclear FAK provides 
a novel twist to the anti-inflammatory effects of FAK inhibition.
Materials and methods
Mice
FAK-KD knockin mice containing a point mutation within the FAK kinase 
domain (changing the codon for Lys454 to Arg) were generated by homol-
ogous recombination, as previously described (Lim et al., 2010a), main-
tained as a heterozygous population, and backcrossed to a C57Bl6 
background (The Jackson Laboratory) for 10 generations. Mouse experi-
ments were approved by the University of California San Diego Institu-
tional Animal Care and Use Committee, and mice were maintained in ac-
cordance with Association for Assessment and Accreditation of Laboratory 
Animal Care International–approved guidelines.
Cells and plasmids
Early-passage FAK-WT and FAK-KD MEFs were generated, immortalized 
by hTERT expression, and maintained on 0.1% gelatin-coated dishes, as 
previously described (Lim et al., 2010a). FAK-WT and FAK-KD ECs were 
isolated, immortalized by large T antigen expression (Addgene), and 
maintained as previously described (Zhao et al., 2010). HUVECs, 293T, 
and Mdm2/p53/ fibroblasts were used as previously described (Lim 
et al., 2008). CHIP/ fibroblasts were obtained from C. Patterson (University 
of North Carolina, Chapel Hill, NC; Dai et al., 2003). Cells were main-
tained in DME with 10% FBS, nonessential amino acids for MEM, 1 mM 
sodium pyruvate, 50 U/ml penicillin, and 50 µg/ml streptomycin. Cell 
culture–based experiments were performed with semiconfluent cells in 
growth media. Mouse GATA4 cDNA was obtained from P. Mellon (University 
of California San Diego, La Jolla, CA; Lawson et al., 1996) and was sub-
cloned into p3XFlagCMV7.1 (Sigma-Aldrich). GST fusion N-terminal 
(aa 1–260; ends with first DNA-binding zinc finger motif) and CT 
(aa 255–440; starts with second zinc finger motif) GATA4 constructs 
(pGEX2T) were obtained from R. Viger (Centre hospitalier de l’Université 
VCAM-1 transcriptional regulation (Karin and Gallagher, 2009). 
Notably, GATA4 is activated by MAPK phosphorylation at 
S105 (van Berlo et al., 2011), and 1 integrin signaling through 
MAPK contributes to GATA4 nuclear translocation and acti-
vation (Liu et al., 2009). As FAK is the major PTK activated by 
integrins and we find that matrix adhesion is required for effi-
cient TNF-–stimulated ERK/MAPK activation and VCAM-1 
production, our results support the importance of FAK activity 
in mediating cross-talk between integrins and cytokine receptor 
signaling pathways.
Although FAK inhibition prevents TNF-–induced GATA4 
S105 phosphorylation, interpretations are complicated by a 
corresponding reduction in GATA4 protein levels. We find that 
genetic or pharmacological FAK inhibition triggers full-length 
FAK protein accumulation in the nucleus and the loss of GATA4 
required for optimal TNF-–induced VCAM-1 expression. FAK-
FERM binds directly to GATA4 and enhances GATA4 poly-
ubiquitination in cells. Expression of a FAK-FERM domain 
containing point mutations in the nuclear localization motif pre-
vents efficient GATA4 di- and polyubiquitination. As FAK-I–
induced loss of GATA4 in cells is blocked by proteasome 
inhibition, our results support the notion that nuclear-localized 
and kinase-inhibited FAK limits VCAM-1 production by pro-
moting GATA4 degradation.
The role of the FAK-FERM domain in GATA4 regulation 
is similar to a study showing that FAK-FERM binds to and in-
hibits the p53 tumor suppressor protein (Golubovskaya et al., 
2005). Cell stress triggers FAK nuclear localization, an FAK– 
p53 complex, and FAK-enhanced Mdm2 E3 ligase–dependent 
ubiquitination and degradation of p53 (Lim et al., 2008). FAK 
serves as a scaffold to limit p53 activity in an FAK kinase–
independent manner. Interestingly, CHIP E3 ligase is required 
Figure 8. Model of FAK function downstream of TNF-a in the regulation 
of VCAM-1 expression. TNF- binding to cell surface receptors triggers 
intracellular signaling cascade activation of MAPKs and NF-B. This leads 
to alterations in gene transcription of targets such as VCAM-1 that is regu-
lated in part by combined effects of AP-1, GATA, and NF-B transcription 
factors. Inhibition of FAK prevents TNF-–induced MAPK activation and the 
inhibition of GATA4 Ser105 phosphorylation. Inhibited FAK (FAK-KD) accu-
mulates in the nucleus, binds directly to GATA4, and promotes increased 
GATA4 ubiquitination and proteasomal degradation via interactions with 
the CHIP E3 ubiquitin ligase. Impairment in both FAK-mediated MAPK acti-
vation and GATA4 stability prevent cytokine-stimulated VCAM-1 transcrip-
tion and reveal novel anti-inflammatory effects of FAK inhibition.
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containing 45,200 50-mer transcripts. Data were collected and evaluated 
by G. Hardiman of the University of California San Diego Biomedical 
Genomics Core facility. Signaling pathway and functional network analy-
ses were performed by IPA software (Ingenuity Systems).
Q-PCR
Q-PCR was used to validate changes in target mRNA level. Total RNAs 
were isolated by the RNeasy kit (QIAGEN), and cDNAs were synthesized 
using random hexamers and reverse transcription (SuperScript III; Life Tech-
nologies). Real-time PCR was performed using AmpliTaq Gold DNA poly-
merase and SYBR green as a substrate (Life Technologies). The primers 
used are mouse GATA4 forward 5-ACCCCAATCTCGATATGTTTG-3, 
GATA4 reverse 5-CCTCGGCATTACGACGCC-3, human VCAM-1 forward 
5-AGTTGAAGGATGCGGGAGTA-3, human VCAM-1 reverse 5-AGAG-
CACGAGAAGCTCAGGA-3, mouse VCAM-1 forward 5-TGAACC-
CAAACAGAGGCAGA-3, and mouse VCAM-1 reverse 5-CGGAATCGT-
CCCTTTTTGTAG-3. Control GAPDH primers were obtained from Life 
Technologies. Quantification of each gene, relative to the calibrator, was 
performed with the equation within Sequence Detections software (v1.2.2; 
Life Technologies).
Biochemical analyses
FAK-I (1 µM PF271) was added to growing cells for 1 h before TNF- ad-
dition (10 ng/ml) unless otherwise indicated. For replating assays, growing 
cells were treated with 0.06% trypsin and 2 mM EDTA in PBS (2.5 min at 
37°C), collected by centrifugation, resuspended in DME with 10% FBS, 
enumerated (Vi-CELL XR; Beckman Coulter), and held at 37°C (2 × 105 
cells/ml) for 30 min. FN-coated (10 µg/ml in PBS overnight) culture dishes 
were blocked with 1% BSA in PBS for 30 min and preheated to 37°C 
before cell replating (1 h) followed by TNF- addition for 15 min to 6 h. 
Cell apoptosis was determined after 7 h by collecting cells with trypsin and 
flow cytometry analyses (FACSCalibur; BD) using allophycocyanin–annexin V 
and 7-actinomycin D staining (BD). Tissue and cultured cell protein lysates 
were prepared in cell extraction buffer containing 50 mM Hepes, pH 7.4, 
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
and 10% glycerol. For immunoprecipitation and GST binding analyses, ly-
sates were diluted twofold in HNTG buffer (50 mM Hepes, pH 7.4, 150 mM 
NaCl, 0.1% Triton X-100, and 10% glycerol) and incubated with antibodies 
(1 µg) or glutathione agarose beads (Sigma-Aldrich) for 3 h at 4°C. Anti-
bodies were collected with either protein A or G Plus (Millipore) agarose 
beads, and beads were washed at 4°C in 1% Triton X-100–only extraction 
buffer followed by washes with HNTG buffer and resolved by SDS-PAGE. 
Densitometry of immunoblotting images was performed using ImageJ 
(v1.44; National Institutes of Health).
To evaluate ubiquitin incorporation into GATA4, experiments were 
performed in human HEK293 or normal Mdm2/p53/ or CHIP/ 
MEFs. MEFs were infected with 50 plaque-forming unit (pfu)/cell Ad-FAK 
or Ad-FAK-FERM constructs and 5 pfu/cell Ad-TA. Controls were performed 
with 50 pfu/cell Ad-TA. For transient transfection, 293T or MEFs using 
jetPRIME (PolyPlus Transfection), 1 µg Flag-GATA4, 0.5 µg HA-ubiquitin 
or His-ubiquitin, and 5 µg FAK-FERM plasmid DNA were used. 40 µM 
MG132 was added 3 h before cell lysis for ubiquitin analyses. For ubiqui-
tin conjugate purification, transfected cells (24 h) were lysed with 8 M urea 
in phosphate buffer (0.1 M NaH2PO4, 10 mM Tris-HCl, pH 8.0, and 20 mM 
imidazole) at room temperature. His-ubiquitin–conjugated proteins were 
bound to a nickel agarose column (Ni–nitrilotriacetic acid; QIAGEN) and 
washed with 8 M urea phosphate buffer, pH 6.3, and proteins were eluted 
in 8 M urea phosphate buffer at pH 4.5.
For fractionation experiments, cells were lysed with Cyt buffer (10 mM 
Tris, pH 7.5, 0.05% NP-40, 3 mM MgCl2, 100 mM NaCl, 1 mM EGTA, 
20 µg/ml aprotinin, 1 mM orthovanadate, and 10 µg/ml leupeptin), scrape 
loaded into tubes, incubated for 5 min at 4°C, and spun at 800 g at 4°C 
(5 min), and cytosolic supernatants were collected. Cell pellets were further 
washed with Cyt buffer, purified nuclei were resuspended in cell extrac-
tion buffer and spun at 16,000 g for 15 min, and the supernatant was 
collected as the nuclear fraction. Samples were separated by SDS-PAGE 
and immunoblotted for GAPDH and PARP as cytoplasmic and nuclear 
markers, respectively.
For direct binding assays, prey proteins were in vitro translated 
using the TNT transcription–translation system (Promega). Various pCDNA3 
FAK expression constructs (1 µg) were translated in a mixture containing 
biotin-labeled Lys and diluted 50 fold into binding buffer (50 mM Hepes, 
pH 7.4, 150 mM NaCl, and 1% Triton X-100). Purified GST-GATA4 pro-
teins were prebound to glutathione agarose beads, incubated with in vitro 
translated prey for 2 h at 4°C, and washed three times in binding buffer, 
and the bound prey were detected by streptavidin-HRP immunoblotting.
Laval Research Centre, Ste-Foy, Quebec, Canada; Tremblay and Viger, 2003). 
Ad tetracycline transactivator (TA) was added to induce various Ad-FAK 
constructs and the indicated HA- or Myc-tagged full-length FAK-WT, 
and FAK-KD, FAK-FERM (aa 1–402, N-terminal fragment), and FAK-CT 
(aa 683–1,024, containing focal adhesion targeting domain) constructs 
were used as previously described (Lim et al., 2008; Schlaepfer et al., 
2007). Lentiviral scrambled (Scr) and anti–human FAK short hairpin RNAs 
were used as previously described (Lim et al., 2008). Mouse CHIP cDNA 
was purchased (Thermo Fisher Scientific), and PCR was used to amplify the 
coding sequence and subcloned into pcDNA3.1 3XHA for expression as 
an HA-tagged protein.
Antibodies and reagents
Anti-FAK (clone 4.47), anti–mouse VCAM-1 (M/K-2), and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; 374) were purchased from Milli-
pore. Anti–mouse VCAM-1 (112702) for blotting was purchased from 
R&D Systems. Anti–pY397 FAK (44625G), anti–pY576 FAK (70013), 
anti-pERK (pT202/pY204; 44654G), and anti-pGATA4 (pS105; 44–948) 
were purchased from Life Technologies. Anti–NF-B pS536 (93H1) and 
anti–p-JNK (pT183/pY185; 9251) were purchased from Cell Signaling 
Technology. Anti–-actin (AC-17), anti-talin (8d4), and anti-Flag (M4) tag 
were purchased from Sigma-Aldrich. Anti–human VCAM-1 (H-276), anti-
IB (C-21), anti-GATA4 (G-4), anti-GATA6 (H-92), anti-JNK2 (D-2), and anti-
ERK2 (12A4) were purchased from Santa Cruz Biotechnology, Inc. 
Anti-HA (16B12) and anti-Myc tag (9E10) were purchased from Covance. 
Anti–poly ADP ribose polymerase (PARP; clone 42), anti-CD31 (MEC13.3), 
and fluorescein isothiocyanate–conjugated anti-CD31 (MEC13.3) were 
purchased from BD. Anti-ubiquitin (Fk2) was purchased from Enzo Life 
Sciences, and anti-GAPDH was purchased from GeneTex Inc. (GTX239). 
Recombinant TNF- (human and mouse) and IL1- (human) were pur-
chased from R&D Systems. Bovine plasma fibronectin (FN) was purchased 
from Sigma-Aldrich. MG132 was purchased from EMD. Mouse GATA4 
ON-TARGETplus SMARTpool siRNA (L-040759-01-0005) and ON-TAR-
GETplus Si Control (Scr) siRNA (D-001810-01) were purchased from 
Thermo Fisher Scientific. 100 pmol siRNA was used to transfect WT MEFs 
using Lipofectamine 2000 (Life Technologies). After 48 h, target knock-
down was confirmed by immunoblotting.
FAK-Is and in vivo TNF-a signaling
FAK-I PF-271 was synthesized by Laviana Corp., as described in patent ma-
terials (Roberts et al., 2008), solubilized in DMSO, and used in experiments 
with cultured cells at 1 µM. FAK-I PND-1186 (Poniard Pharmaceuticals) was 
used for in vivo mouse experiments (Tanjoni et al., 2010; Walsh et al., 
2010), solubilized in water, and administered twice daily via oral gavage 
(100 mg/kg) to either pregnant female C57Bl6 mice from E7.5 to E9.0 or 
to C57Bl6 mice 36 h before initiation of in vivo signaling assays. Recombi-
nant TNF- (0.02 mg/kg in 100 µl PBS) or PBS was tail vein injected into 
C57BL6 mice, and after 5 min or 6 h, tissues were rapidly excised and 
either homogenized for protein lysates or embedded in optimal cutting 
temperature (Tissue Tech) compound and flash frozen for sectioning.
Embryo staining
Timed matings were performed with FAKWT/KD heterozygous mice, and 
embryo development was visualized by ultrasound, surgically harvested at 
E9.0–9.5, and fixed in 3.7% PFA. For whole-mount staining, fixed em-
bryos were permeabilized (0.1% Triton X-100 in PBS for 4 h), blocked (1% 
BSA and 1% goat serum in PBS for 2 h), incubated with anti–VCAM-1 (di-
luted at 1:100) and biotinylated goat anti–rat IgG (diluted at 1:300) using 
the VECTASTAIN Elite ABC kit, and visualized with a diaminobenzidine-
based substrate (Vector Laboratories). Controls were performed without 
primary antibody addition. Bright field images of dissected and stained 
embryos were acquired at room temperature using a stereo microscope 
(M2Bio; Carl Zeiss) at 1.0× (Achromat S, FWD 69 mm) with a color charge-
coupled device camera (INFINITY1; Lumenera Corporation). Embryos em-
bedded in paraffin were thin sectioned and stained with hematoxylin and 
eosin. Images were acquired at room temperature using an inverted micro-
scope (IX81; Olympus) at 4× (UPlanS Apo, NA 0.16) with a color charge-
coupled device camera (INFINITY1) All images were cropped, and con-
trast was adjusted using Photoshop CS3 (Adobe).
Gene array and functional analysis
10 FAKWT/WT and FAKKD/KD E9.5 embryos were surgically harvested, 
pooled, stored in RNAlater (Life Technologies), and total RNA from tissue 
samples was isolated using RNeasy (QIAGEN). RNA quality was verified 
using the Bioanalyzer (Agilent Technologies). cDNAs were synthesized 
and hybridized to an Illumina mouse WG-6 v2.0 expression bead chip 
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